NTRA stock pre-market at EUR 361.25: laboratory testing group
Published on 10/26/2026 at 08:12 | Editorial responsibility: Rafael MĂĽller, Editor-in-Chief AD HOC NEWSNatera testing platform
- Natera develops cell-free DNA tests for women’s health, oncology, and organ health.
- The pre-market article is dated October 26, 2026.
- NTRA stock trades pre-market at EUR 361.25 at 8:07 a.m. CET at Lang & Schwarz on October 26, 2026.
Natera develops cell-free DNA tests for women’s health, oncology, and organ health, using molecular biology, bioinformatics software, and artificial intelligence in its testing platform, according to the company’s investor relations site. Natera stock trades pre-market at EUR 361.25 at 8:07 a.m. CET at Lang & Schwarz on October 26, 2026.
Pre-market trading
The company’s platform includes the Panorama prenatal test, the Signatera tumor-specific assay, and the Prospera kidney-transplant rejection assessment, according to the same company source. Natera operates laboratories in Austin, Texas, and San Carlos, California, certified under the Clinical Laboratory Improvement Amendments.
Business and market context
Natera earns revenue from genetic testing and diagnostic services across women’s health, oncology, and organ health. The company says its tests are supported by more than 400 peer-reviewed publications and that its laboratories are ISO 13485-certified and CAP-accredited.
The further course from the Xetra open at 9:00 a.m. CET is shown by the continuously updated real-time quote of Natera stock.
Market context: Market report S&P 500.
